Literature DB >> 9356863

Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients.

A el S Mohamed1, M A al Karawi, G A Mesa.   

Abstract

BACKGROUND/AIMS: The purpose of this study was to assess the clinical and histological significance of dual infection with Hepatitis C virus and Hepatitis B virus.
METHODOLOGY: The clinical presentation and histologic findings of 20 patients with HCV and HBV were reviewed and compared to 33 patients with only HCV, as controls. None of the patients were treated and none had anti-HDV or HIV 1/HIV2.
RESULTS: The patients with dual HCV and HBV infection had more decompensated liver disease. Most of these patients were classified in the Child-Pugh group C as compared to the controls (36.8% vs 0%, p < 0.01). Liver cirrhosis was more common in patients with HCV and HBV infection than it was in the controls infected with HCV only (95% vs 48.5%, p < 0.01). Similarly, hepatocellular carcinoma was more common in patients with dual HCV and HBV infection than it was in the controls (63% vs 15%, p < 0.01).
CONCLUSION: Liver disease seems to be more severe in patients with dual HCV and HBV infection than in patients with HCV infection only, both clinically and histologically.

Entities:  

Mesh:

Year:  1997        PMID: 9356863

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  19 in total

1.  Frequency of HIV and HCV Co-Infections in Chronic HBV Patients Referred to Taleghani Hospital, Tehran, Iran from 2006 to 2010.

Authors:  Seyed Mohammad Ebrahim Tahaei; Seyed Reza Mohebbi; Pedram Azimzadeh; Mohsen Vahedi; Shohreh Almasi; Sara Romani; Afsaneh Sharifian; Faramarz Derakhshan; Mohammad Reza Zali
Journal:  Hepat Mon       Date:  2011-12-20       Impact factor: 0.660

2.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

3.  Prognostic factors associated with hepatitis C disease: a case-control study utilizing U.S. multiple-cause-of-death data.

Authors:  Matthew Wise; Lyn Finelli; Frank Sorvillo
Journal:  Public Health Rep       Date:  2010 May-Jun       Impact factor: 2.792

4.  Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony.

Authors:  Shailaja Jamma; Ghazi Hussain; Daryl T-Y Lau
Journal:  Curr Hepat Rep       Date:  2010

Review 5.  Hepatitis B virus and hepatitis C virus dual infection.

Authors:  Gaia Caccamo; Francesca Saffioti; Giovanni Raimondo
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

6.  Isolated antibody to hepatitis B core antigen in patients with chronic hepatitis C virus infection.

Authors:  Ahmed Helmy; Mohammed-Ibrahim Al-Sebayel
Journal:  World J Gastroenterol       Date:  2006-07-21       Impact factor: 5.742

7.  Frequency of HBV, HCV and HIV infections among hospitalized injecting drug users in Kashan.

Authors:  M Sharif; Alireza Sherif; Mansour Sayyah
Journal:  Indian J Sex Transm Dis AIDS       Date:  2009-01

8.  The impact of antiviral therapy and the influence of metabolic cofactors on the outcome of chronic HCV infection.

Authors:  Marcello Persico; Savino Bruno; Andrea Costantino; Marta Mazza; Piero Luigi Almasio
Journal:  Int J Hepatol       Date:  2011-11-15

9.  Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus.

Authors:  Yu Jin Kim; Jin Woo Lee; Yun Soo Kim; Sook Hyang Jeong; Young Seok Kim; Hyung Joon Yim; Bo Hyun Kim; Chun Kyon Lee; Choong Kee Park; Sang Hoon Park
Journal:  Korean J Hepatol       Date:  2011-09

Review 10.  The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis.

Authors:  Jun-Ying Liu; Yun-Jian Sheng; Huai-Dong Hu; Qing Zhong; Jing Wang; Shi-Wen Tong; Zhi Zhou; Da-Zhi Zhang; Peng Hu; Hong Ren
Journal:  Virol J       Date:  2012-09-06       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.